**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript No: 6644**

**Columns: Case Control Study**

**Association between obesity-related adipokines and colorectal cancer: A case-control study and meta-analysis**

Joshi RK *et al*. Obesity-related adipokines and colorectal cancer

Rakhi Kumari Joshi, Woo Jin Kim, Sang-Ah Lee

**Rakhi Kumari Joshi, Sang-Ah Lee,** Department of Preventive Medicine, Kangwon National University School of Medicine, Chuncheon-si, Gangwon-do 200-701, South Korea

**Woo Jin Kim,** Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon-si, Gangwon-do 200-701, South Korea

**Author contributions:** Lee SA designed the research, contributed to writing the manuscript, assisted in revisions to approved the final version of the manuscript; Kim WJ provided the blood samples and contributed to approve the final version of manuscript; Joshi RK performed the statistical analysis and wrote the manuscript.

**supported by** Korean Ministry of Health and Welfare through the National R and C Program of Cancer Control (1020420); and 2010 Research Grant from Kangwon National University

**Correspondence to: Sang-Ah Lee, PhD,** Department of Preventive Medicine, Kangwon National University School of Medicine, 1 Kangwondaehak-gil, Chuncheon-si, Gangwon-do, 200-701, South Korea. sangahlee@kangwon.ac.kr

**Telephone:** +82-33-2508871 **Fax:** +82-33-2508809

**Received:** October 25, 2013 **Revised:** January 24, 2014

**Accepted:** April 8, 2014

**Published online:**

**Abstract**

**AIM:** To examine the association between obesity-related adipokines (adiponectin, leptin, resistin, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) and colorectal cancer (CRC) risk.

**METHODS**: Serum levels of adipokines were measured in 100 CRC patients and age- and sex-matched controls for the data analysis. Unconditional logistic regression models were used for estimating odds ratios (ORs) and 95% confidence intervals (CIs) related to each adipokine. For the meta-analysis, studies published before July 2013 available on Medline/PubMed and EMBASE were retrieved. The analysis included a total of 17 relevant studies (including the present case-control study): nine studies on adiponectin and eight on leptin. The effect sizes of ORs and 95%CIs were estimated using RevMan 5.1. Heterogeneity was evaluated using Cochran’s Q-test and *I2* statistics.

**RESULTS**: Among the five adipokines, only resistin levels were significantly higher in cases than in controls (*P* < 0.001). The case-control study results showed no association between adiponectin and CRC and a negative association between leptin and CRC. However, the results of the meta-analysis showed a significant inverse association between adiponectin and CRC (OR = 0.91, 95%CI: 0.83-1.00, *P* = 0.04) and no association between CRC and leptin. After stratification by study design, an inverse association between adiponectin and CRC was observed in prospective studies only (OR = 0.90, 95%CI: 0.82-0.99, *P* = 0.03), whereas the association between leptin and CRC was inconsistent (prospective studies: OR = 1.14, 95%CI: 1.02-1.27, *P* = 0.02 and retrospective studies: OR = 0.47, 95%CI: 0.29-0.74, *P* = 0.001). The associations of resistin and TNF-α with CRC risk were positive, but no association was observed for IL-6.

**CONCLUSION**: Our results suggest a negative association of leptin, positive associations of resistin and TNF-α, and null associations of adiponectin and IL-6 with CRC. However, further studies with larger number of prospective approaches are needed.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Obesity; Colorectal cancer; Cancer risk; Adipokines; Obesity-related adipokines

**Core tip:** Evidence from the previous studies indicates that there is an association of obesity-related adipokines and pro-inflammatory cytokines with colorectal cancer risk, but the results are inconsistent. In this study, a case-control study and meta-analysis were performed to investigate the possible association of adipokines (adiponectin, leptin, and resistin) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α) with colorectal cancer risk. Although we did not find any significant results, case-control study and meta-analysis results support a previous report and suggest that obesity-related adipokines could be risk factors for colorectal cancer; however, further studies with larger number of prospective approaches are needed.

Joshi RK, Kim WJ, Lee SA. Association between obesity-related adipokines and colorectal cancer: A case-control study, and meta-analysis.

**Available from:**

**DOI:**

**INTRODUCTION**

Colorectal cancer (CRC) is a major public health concern, as it is one of the leading causes of cancer deaths worldwide. Although the highest incidence rate of CRC is observed in developed countries, including Australia, New Zealand, Canada, and the United States, as well as countries in North Western Europe, its incidence rate has been rapidly increasing in developing countries in the past few decades[[1](#_ENREF_1)]. In particular, East Asian countries such as China, Japan, South Korea, and Singapore have experienced a two- to four-fold increase in CRC incidence in recent decades[[2](#_ENREF_2),[3](#_ENREF_3)]. In South Korea, the incidence of CRC increased from 20.4 per 100000 to 35.9 per 100000 from 1999 to 2010, with a 5.9% annual percentage change in age-standardized incidence rates[[4](#_ENREF_4)].

Obesity, particularly central obesity, has been consistently identified as the most recognized risk factor for CRC[[5](#_ENREF_5),[6](#_ENREF_6)]. Furthermore, obesity is significantly associated with a 7%-60% increase in CRC risk compared to normal weight individuals (BMI < 25 kg/m2)[[7-9](#_ENREF_7)]. However, the etiologic mechanisms underlying this association are not well understood. It is hypothesized that insulin and adipokines are key regulators for the potential link between obesity and CRC. First, obesity may lead to insulin resistance and hyperinsulinemia, which consequently reduces IGFBP-1 levels while elevating levels of IGF-1; it also increases cell proliferation and inhibits apoptosis[[10-13](#_ENREF_10)]. Second, obesity alters the level of adipose tissue-derived adipokines, including adiponectin, leptin, and resistin, and pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Increased levels of these adipokines can cause initiation, progression, and metastasis of tumors, with the exception of adiponectin, which has anti-inflammatory and insulin-sensitizing properties[[14](#_ENREF_14),[15](#_ENREF_15)]. Experimental studies have demonstrated that pro-inflammatory cytokines such as IL-6 and TNF-α may promote tumor growth by acting as mitogens for normal and neoplastic colon cells[[15](#_ENREF_15)] and by inducing leptin and resistin production[[16](#_ENREF_16),[17](#_ENREF_17)], which stimulates survival and growth of colon cancer cells directly or indirectly by increasing IL-6 and TNF-α[[16](#_ENREF_16),[18](#_ENREF_18)]. In contrast, adiponectin has anti-carcinogenic effects, including inhibition of cell growth and induction of apoptosis[[19](#_ENREF_19)].

Due to the bioactivities of adipokines, several prospective and retrospective epidemiologic studies have examined the association between circulating levels of adipokines related to CRC risk; however, the results have been inconclusive. Although few prospective studies[[20-22](#_ENREF_20)] have shown an inverse association between low adiponectin and CRC, other studies have found conflicting results[[23](#_ENREF_23),[24](#_ENREF_24)]. It has been suggested that CRC risk increases with increased levels of leptin[[21](#_ENREF_21),[25](#_ENREF_25)] and resistin[[23](#_ENREF_23),[26](#_ENREF_26)], yet this increase is unsupported by other studies[[27](#_ENREF_27),[28](#_ENREF_28)]. Similarly, three prospective studies[[21](#_ENREF_21),[29](#_ENREF_29),[30](#_ENREF_30)] on IL-6 and TNF-α, have reported inconsistent results. Although there are some discrepancies among studies, it could be speculated that circulating levels of adipokines are possible candidate biomarkers for CRC risk. Thus, early identification of such risk factors can be useful for screening purposes and may help prevent and control CRC.

The aim of the present case-control study is to assess the association of five adipocytokines (adiponectin, leptin, resistin, TNF-α, and IL-6) with CRC risk and to perform a meta-analysis using results from different countries to describe the effect of adiponectin and leptin on CRC risk.

**MATERIALS AND METHODS**

***Patients and samples***

The specimens used for this study were collected from the Keimyung Human Bio-Resource Bank (KHBB), a member of the National Bio-bank of South Korea, which is supported by the Ministry of Health and Welfare, South Korea and Kangwon National University Bio-bank (KNUB). All of the samples were therefore derived from the National Bio-bank of South Korea and subject to informed consent under institutional review board-approved protocols. After the study protocols were approved, the study was conducted at Keimyung and Kangwon National University Hospital from 2009-2011. Patients from Keimyung University Hospital who had been newly and pathologically diagnosed with colorectal cancer by biopsy using colonoscopy were identified as colorectal cancer patients. Similarly, age- and sex-matched controls from Kangwon National University Hospital were identified among individuals who received negative diagnoses for colorectal cancer by serological blood test. The cases and controls were then subsequently matched for each 100:100 as selected for the study. The age strata for the analysis were ≤ 60, 61-70, and 71 ≥ in selected cases and controls. The study was approved by the National Bio-bank of South Korea, and all participants provided informed consent under institutional review board-approved protocols (IRB No. 2010-10-008).

***Measurement of serum adipokines***

Blood samples were collected from the patients and age/sex-matched individuals. Serum separated from the blood samples was stored at -20 °C for further analysis. Serum levels of adiponectin were determined by enzyme-linked immunosorbent assay (ELISA) (AdipoMark, South Korea) per the manufacturer’s instructions, with a sensitivity of 1.39 ng/ml and an intra-assay coefficient of variation of 4.1%-5.9%. ELISA (Enzo Life Science, United States) was used to measure leptin with a sensitivity of 23.4 pg/ml and an intra-assay coefficient of variation of 4.4%-13.4%. Resistin levels were measured using a resistin (human) ELISA kit (Adipogen, Switzerland) with a sensitivity of 100 pg/ml and an intra-assay coefficient of variation 2.86%-3.73%. Enzyme Immunoassay (EIA) (Enzo Life Science, United States) was used to measure the serum levels of IL-6 and TNF-α. The sensitivities of IL-6 and TNF-α were 6.01 pg/ml and 8.43 pg/ml, respectively, and the intra-assay coefficients of variations were 3.8%-6.4% and 4.5%-3.6%, respectively.

***Meta-analysis***

To collect the studies for the meta-analysis, we searched the PubMed/Medline and EMBASE databases using the following keywords for published papers: “plasma and/or serum”, “adiponectin and/or leptin” and “colorectal cancer”. The articles included in this meta-analysis were all eligible prospective and retrospective studies on CRC published before July 2013. The studies that included odds ratio (OR) or relative risk (RR) but did not use original data to calculate these values were excluded. The study selection strategy is presented in Figure 1. We included a total of eight studies on adiponectin and CRC and seven studies on leptin and CRC. The number of the cases and controls varied widely among studies. Therefore, for the meta-analysis we used median variables; if the study group was categorized by quartile, we rearranged the number by median, as q1 and q2 (reference group) *vs* q3 and q4 (compared group). Likewise, if the study group was categorized by quintile, we rearranged the number as 1st, 2nd and 3rd quintile (reference group) *vs* 4th and 5th quintile (compared group). Next, the pooled odds ratios from the selected studies were calculated to evaluate the strength of the association of adiponectin and leptin with CRC, which is presented as the result of the current meta-analysis. Cochran’s *χ2*test[[31](#_ENREF_31)] and the inconsistency index (*I*2)[[32](#_ENREF_32)] were used to evaluate heterogeneity across the studies. To calculate the summary OR, a fixed-effect model was used if *P* > 0.10 or *P* ≤ 0.10, but *I*² ≤ 50% indicates lack of heterogeneity[[33](#_ENREF_33)]. Otherwise, a random-effects model was used when *P* ≤ 0.10 and *I*² > 50%, which indicates significant heterogeneity[[34](#_ENREF_34)]. To determine the statistical significance of pooled the odds ratios, *Z*-tests were performed and considered significant when *P* < 0.05. Additionally, we performed a stratification analysis of the study designs (prospective *vs* retrospective) to explore the association of adiponectin and leptin with CRC. Finally, potential publication bias was assessed using Begg’s funnel plot and Egger’s regression test[[35](#_ENREF_35),[36](#_ENREF_36)]. *P* < 0.05 was chosen as the level of statistical significance for publication bias.

***Statistical analysis***

The baseline characteristics of colorectal cancer cases and controls were compared using a *t*-test for continuous variables and a *χ2* test for categorical variables. The association between adipokines and CRC was examined *via* unconditional logistic regression model expressed as univariate odds ratios (OR1s) and multivariate odds ratios (OR2s) with 95% confidence intervals (CIs) after adjusting for age, sex and covariates, including the selected adipokines. To calculate odds ratios, a median value was used for resistin due to the skewed blood level distribution, and tertiles that were used for rest of the adipokines. Furthermore, we performed the analysis assuming all selected adipokines as continuous variables and as categorical variables in tertiles to assess the cumulative risk effects of adipokines on CRC. Each adipokines was coded as 1, 2, or 3 for adiponectin and 0, 1, or 2 for other adipokines and was calculated using the sum of the numbers. Statistical analyses were performed using SAS statistical software (version 9.2, SAS Institute) for case-control study analysis and RevMan software (version 5.1, Cochrane Collaboration) and STATA Software (version 10.0) for the meta-analysis.

**RESULTS**

Table 1 shows the baseline characteristics of case and control participants. Of the total participants, 60% were male and 40% were female. The corresponding mean values for serum adipokines were 6.0 ± 4.9 µg/ml, 7.8 ± 8.9 ng/ml, 3.9 ± 2.3 ng/ml, 21.0 ± 103.6 pg/ml, and 6.0 ± 13.2 pg/ml for adiponectin, leptin, resistin, IL-6, and TNF-α, respectively. The mean levels of all examined adipokines were very similar in cases and controls, except for resistin, which was significantly higher in cases (4.9 ± 2.3 ng/ml) than in controls (2.8 ± 1.7 ng/ml) (*P* ≤ 0.0001) (Table 1).

 The results of the univariate and multivariate logistic regression analyses for the association between each adipokines and CRC are shown in Table 2. Serum levels of resistin and TNF-α were significantly positively associated with the risk of CRC; moreover, the association was increased significantly for both adipokines after adjusting covariates (OR = 6.08, 95%CI: 3.23-11.44 and OR = 41.16, 95%CI: 12.62-134.23; *P-*trend ≤ 0.01, respectively). An inverse association was observed between leptin and CRC, and the association remained consistent even after adjusting covariates (OR = 0.31, 95%CI: 0.14-0.73; *P-*trend = 0.01). In contrast, there was no association with adiponectin and IL-6 and CRC risk (Table 2). Additionally, we evaluated the association among the combined score of the adipokines and risk of CRC; however we found no combined effect using the weighted score of each adipokines (data not shown).

 The results of the meta-analysis using prospective and retrospective studies including the present study showed adiponectin to be negatively associated with CRC risk (OR = 0.91, 95%CI: 0.83-1.00, *P* = 0.04). After stratification, the association remained significant, predominantly in prospective studies (OR = 0.90, 95%CI: 0.82-0.99, *P* = 0.03) (Figure 2). For leptin, no significant association with CRC was observed; however, in an analysis stratified by study design (prospective *vs* retrospective), a positive association was observed in prospective studies (OR = 1.14, 95%CI: 1.02-1.27, *P* = 0.02), while a negative association was observed in retrospective studies (OR = 0.47, 95%CI: 0.29-0.74, *P* = 0.001) (Figure 3). Publication bias of the meta-analysis regarding the association of adiponectin and leptin with CRC was also examined, but the evaluation of publication bias did not yield statistically significant results (data not shown).

**DISCUSSION**

In our case-control study using a Korean population, adiponectin was not associated with CRC risk; however, the overall results of meta-analysis suggest a significant inverse association of adiponectin with CRC risk, particularly in prospective studies. For leptin, we found a significant inverse association with CRC in our case-control study, although the meta-analysis showed no association. Furthermore, after stratification by study design, the association was found to be inconsistent; negative association was observed in the meta-analysis using retrospective studies, while a positive association was observed in the prospective studies. For the other selected adipokines, including resistin, IL-6 and TNF-α, we found a significant positive association of resistin and TNF-α with CRC risk, but no association of IL-6 with CRC risk.

 It has been proposed that adiponectin may inhibit CRC cell growth and proliferation through several pathways, including the STAT3/ NF-κB, AMPK, and MAPK pathways, resulting in a protective effect on CRC risk[[37](#_ENREF_37)]. Several epidemiological studies have examined the association between low circulating adiponectin and increased risk of CRC[[28](#_ENREF_28),[38](#_ENREF_38),[39](#_ENREF_39)], but other studies have not supported this association[[23](#_ENREF_23),[24](#_ENREF_24)]. Thus far, among the several prospective studies that have been conducted[[20](#_ENREF_20),[21](#_ENREF_21),[24](#_ENREF_24),[40-42](#_ENREF_40)], two studies from an EPIC[[20](#_ENREF_20)] and WHI-OS[[21](#_ENREF_21)] have suggested that an inverse association between low adiponectin and CRC was attenuated and did not retain significance after adjusting for BMI and WC. Other studies[[40](#_ENREF_40),[41](#_ENREF_41)] have proposed that men with the highest concentrations of adiponectin had reduced risk for CRC compared to men with the lowest concentrations, even after adjusting for BMI. However, two studies[[24](#_ENREF_24),[42](#_ENREF_42)] could not confirm the significant differences regarding the level of adiponectin among CRC patients and controls, and they also failed to describe the association. In retrospective studies, the results regarding an association between adiponectin and CRC are also inconsistent. Two case-control studies[[43](#_ENREF_43),[44](#_ENREF_44)] have consistently reported a significantly increased risk of CRC in patients with decreased levels of adiponectin, predominantly for early cancer, with the risk persisting even after adjusting for BMI, WHR, or other lifestyle factors. In contrast, a study[[23](#_ENREF_23)] conducted in Japan did not find any association between adiponectin and CRC among BMI matched cases and controls. In the present study, we were unable to find any differences in adiponectin level between cases and control and did not observe any association; however, our meta-analysis results showed an inverse association between adiponectin and CRC risk, which is consistent with another recently published meta-analysis[[45](#_ENREF_45)]. Furthermore, after stratifying by ethnicity, the inverse association between adiponectin and CRC was stronger among Asians compared to Caucasians (results not shown). The difference in ethnicity, however, must be interpreted with caution due to the lack of power based on the small number of studies among Asian populations compared to the number conducted in Caucasian populations. Therefore, further investigations that include other ethnic groups, including other Asians, are needed to confirm and expand these findings.

 In contrast to adiponectin, leptin has tumorigenic bioactivity and regulates angiogenesis or apoptosis through several signaling pathways, including the PI3K/Akt pathway *via* up-regulation of IRS, JAK/STAT3 and the mitogenic pathway *via* ERK1/2 or JNK[[37](#_ENREF_37)]. The association between leptin levels and CRC risk remains controversial. In the present study, the finding of an inverse association between leptin and CRC is consistent with previously published case-control studies[[27](#_ENREF_27),[28](#_ENREF_28),[46](#_ENREF_46)]. The results from our meta-analysis indicated that elevated levels of leptin are not associated with CRC risk, which is consistent with another recent meta-analysis[[47](#_ENREF_47)]. However, while a negative association between leptin and CRC risk has been observed in retrospective studies after stratification by study design, the association has been positive in prospective studies. In contrast, most previous prospective studies[[21](#_ENREF_21),[25](#_ENREF_25),[48](#_ENREF_48),[49](#_ENREF_49)] reported a positive association between elevated leptin levels and CRC risk after adjustment for BMI or WC, whereas one study[[49](#_ENREF_49)] reported that leptin is associated CRC risk independently of BMI. Additionally, the results from our meta-analysis among Asians and Caucasians, showed a significant positive association between leptin and CRC only among Caucasians. However, it is difficult to compare the differences between Asians and Caucasians due to the limited amount of available research. It was also found that circulating leptin levels were relatively higher in Caucasians than Asians[[50](#_ENREF_50)]. Overall, the inconsistencies in the literature may be due to variations in sample size, study design, or adjustment of different confounders.

 It has been suggested that high resistin levels are related to cancer-associated chronic inflammation. Resistin exhibits potent pro-inflammatory properties by up-regulating the expression of IL-6 and TNF-thereby enhancing its own activity by positive feedback through the NF-kB signaling pathway[[17](#_ENREF_17)]. The studies examining the association of resistin, IL-6, and TNF-with CRC are limited in number. A few retrospective studies[[23](#_ENREF_23),[26](#_ENREF_26),[28](#_ENREF_28),[51](#_ENREF_51),[52](#_ENREF_52)] have reported that the resistin levels in CRC patients are higher than those in controls, and a significant positive association of resistin with CRC was demonstrated in only two studies[[23](#_ENREF_23),[26](#_ENREF_26)]. Likewise, in our case-control study, we observed significantly elevated levels of resistin in CRC patients and an association between those elevated levels and CRC risk. Previous prospective studies[[21](#_ENREF_21),[29](#_ENREF_29),[30](#_ENREF_30),[53](#_ENREF_53)] have indicated that there is no significant association between IL-6 and CRC. Although two studies, a cohort from WHI-OS[[21](#_ENREF_21)] and an HPFS study[[53](#_ENREF_53)], reported an association of IL-6 with increased risk of CRC, it was suggested that the association was likely mediated by insulin[[21](#_ENREF_21)], and the association was observed predominantly among lean men (BMI < 25 kg/m2), as opposed to men with BMI ≥ 25 kg/m2. Our results are consistent with the findings of previous case-control studies that did not find any significant association between circulating IL-6 levels and CRC risk[[39](#_ENREF_39),[54](#_ENREF_54)]. Of the published studies, only a few[[21](#_ENREF_21),[29](#_ENREF_29),[39](#_ENREF_39)] have examined the association of TNF-with CRC risk and found null results. As this is the first time that we found a significant positive association between TNF-and CRC risk, our findings should be interpreted with caution. Thus, to improve the understanding of the association of resistin, IL-6, and TNF-with CRC, further investigation with a larger number of cases and controls and prospective studies are needed to accurately assess the possibility that circulating levels of these adipokines are associated with increased risk of CRC.

 This study describes the simultaneous measurement of selected adipokines for covariate assessment to evaluate their association with CRC risk becauseIL-6 and TNF-may promote tumor growth as mitogens and induce leptin and resistin production while reducing adiponectin, which stimulates growth of colon cancer cells directly or indirectly by increasing IL-6 and TNF-Our case-control study included a higher number of participants (100:100) than previous case-control studies (number of cases and controls less than 100). Additionally, we conducted a meta-analysis and presented the overall results of the association of adiponectin and leptin with CRC according study design; no publication bias was detected, which indicates that the results should be unbiased.

 Our study has some limitations. In the case-control study, we used a single measurement of serum adipokines at baseline, which may be susceptible to short-term variation and could bias results towards the null; additionally, we did not include confounding factors such as BMI, smoking status, or alcohol consumption. Likewise, our meta-analysis was based on unadjusted OR estimates because we could not match the confounding factors due to variations in adjusted confounders among selected studies.

 In summary, although the meta-analysis suggested an inverse association of adiponectin with CRC, we did not find any association in our case-control study. Leptin was inversely associated with cancer risk in our case-control study, but the meta-analysis did not support this association. In addition, the serum resistin and TNF-α, but not IL-6, were positively associated with CRC risk after adjustment of selected adipokines as covariates. In conclusion, our results do not show a causal relationship between obesity-related adipokines and colorectal cancer risk. Therefore, further studies with larger populations and prospective approach are needed to support the association between these selected adipokines and CRC.

**COMMENTS**

***Background***

Colorectal cancer (CRC) is a leading cause of death worldwide. Previous studies have suggested an association between obesity-related adipokines and CRC risk, but prospective data are limited and the results are still inconclusive.

***Research frontiers***

Although several prospective and retrospective studies have demonstrated the association of various obesity-related adipokines and pro-inflammatory cytokines with CRC risk, the results are still inconclusive. To gain further insight into the association of adipokines (adiponectin, leptin, resistin) and pro-inflammatory cytokines (IL-6 and TNF-α) with CRC risk, we performed a case-control study and meta-analysis.

***Innovations and breakthroughs***

In the present case-control study using a Korean population, adiponectin was not associated with CRC risk; however, the meta-analysis, which included our results, suggests a significant inverse association of adiponectin with CRC risk. Our case-control study found an inverse association of leptin with CRC, but the results of the meta-analysis did not indicate any association. For the other adipokines, there was a positive association of resistin and TNF-αwith CRC risk, but no association of IL-6 with cancer risk.

***Applications***

This study supports the understanding of the association of obesity-related adipokines with CRC risk, possibly representing a future strategy for large prospective studies, which may lead to improved identification of individuals at risk of developing CRC.

***Peer review***

This is a case-control study among 100 cancer patients with age- and sex-matched controls and a meta-analysis of currently available studies, including our study results, on the association of adiponectin and leptin with CRC. The study addresses the important topic of the association of obesity-related adipokines with CRC risk. The results are interesting and suggest that further prospective studies with a larger number of subjects are warranted.

**REFERENCES**

1 **Boyle P,** Levin B. World cancer report 2008. Lyon: IARC Press 2008

2 **Boyle P**, Langman JS. ABC of colorectal cancer: Epidemiology. *BMJ* 2000; **321**: 805-808 [PMID: 11009523]

3 **Sung JJ**, Lau JY, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. *Lancet Oncol* 2005; **6**: 871-876 [PMID: 16257795 DOI: 10.1016/S1470-2045(05)70422-8]

4 **Jung KW**, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. *Cancer Res Treat* 2013; **45**: 1-14 [PMID: 23613665 DOI: 10.4143/crt.2013.45.1.1]

5 **Ning Y**, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. *Obes Rev* 2010; **11**: 19-30 [PMID: 19538439 DOI: 10.1111/j.1467-789X.2009.00613.x]

6 **Ma Y**, Yang Y, Wang F, Zhang P, Shi C, Zou Y, Qin H. Obesity and risk of colorectal cancer: a systematic review of prospective studies. *PLoS One* 2013; **8**: e53916 [PMID: 23349764 DOI: 10.1371/journal.pone.0053916]

7 **Moghaddam AA**, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. *Cancer Epidemiol Biomarkers Prev* 2007; **16**: 2533-2547 [PMID: 18086756 DOI: 10.1158/1055-9965.EPI-07-0708]

8 **Dai Z**, Xu YC, Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. *World J Gastroenterol* 2007; **13**: 4199-4206 [PMID: 17696248]

9 1 **Larsson SC**, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. *Am J Clin Nutr* 2007; **86**: 556-565 [PMID: 17823417]

10 **Kahn BB**, Flier JS. Obesity and insulin resistance. *J Clin Invest* 2000; **106**: 473-481 [PMID: 10953022 DOI: 10.1172/JCI10842]

11 **Gunter MJ**, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Howard BV, Wylie-Rosett J, Anderson GL, Ho GY, Kaplan RC, Li J, Xue X, Harris TG, Burk RD, Strickler HD. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. *Cancer Res* 2008; **68**: 329-337 [PMID: 18172327 DOI: 10.1158/0008-5472.CAN-07-2946]

12 **Sandhu MS**, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. *J Natl Cancer Inst* 2002; **94**: 972-980 [PMID: 12096082]

13 **Otani T**, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. *Int J Cancer* 2007; **120**: 2007-2012 [PMID: 17266031 DOI: 10.1002/ijc.22556]

14 **Tilg H**, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nat Rev Immunol* 2006; **6**: 772-783 [PMID: 16998510 DOI: 10.1038/nri1937]

15 **Grivennikov SI**, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. *Ann Rheum Dis* 2011; **70** Suppl 1: i104-i108 [PMID: 21339211 DOI: 10.1136/ard.2010.140145]

16 **Otero M**, Lago R, Lago F, Casanueva FF, Dieguez C, Gómez-Reino JJ, Gualillo O. Leptin, from fat to inflammation: old questions and new insights. *FEBS Lett* 2005; **579**: 295-301 [PMID: 15642335 DOI: 10.1016/j.febslet.2004.11.024]

17 **Bokarewa M**, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. *J Immunol* 2005; **174**: 5789-5795 [PMID: 15843582]

18 **McTernan PG**, Kusminski CM, Kumar S. Resistin. *Curr Opin Lipidol* 2006; **17**: 170-175 [PMID: 16531754 DOI: 10.1097/01.mol.0000217899.59820.9a]

19 **Sugiyama M**, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, Nozaki Y, Fujita K, Yoneda M, Wada K, Nakagama H, Nakajima A. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. *Int J Oncol* 2009; **34**: 339-344 [PMID: 19148467]

20 **Aleksandrova K**, Boeing H, Jenab M, Bueno-de-Mesquita HB, Jansen E, van Duijnhoven FJ, Fedirko V, Rinaldi S, Romieu I, Riboli E, Romaguera D, Westphal S, Overvad K, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Kaaks R, Lukanova A, Trichopoulou A, Lagiou P, Trichopoulos D, Agnoli C, Mattiello A, Saieva C, Vineis P, Tumino R, Peeters PH, Argüelles M, Bonet C, Sánchez MJ, Dorronsoro M, Huerta JM, Barricarte A, Palmqvist R, Hallmans G, Khaw KT, Wareham N, Allen NE, Crowe FL, Pischon T. Total and high-molecular weight adiponectin and risk of colorectal cancer: the European Prospective Investigation into Cancer and Nutrition Study. *Carcinogenesis* 2012; **33**: 1211-1218 [PMID: 22431719 DOI: 10.1093/carcin/bgs133]

21 **Ho GY**, Wang T, Gunter MJ, Strickler HD, Cushman M, Kaplan RC, Wassertheil-Smoller S, Xue X, Rajpathak SN, Chlebowski RT, Vitolins MZ, Scherer PE, Rohan TE. Adipokines linking obesity with colorectal cancer risk in postmenopausal women. *Cancer Res* 2012; **72**: 3029-3037 [PMID: 22511581 DOI: 10.1158/0008-5472.CAN-11-2771]

22 **Touvier M**, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, Méjean C, Latino-Martel P, Hercberg S, Galan P, Czernichow S. Pre-diagnostic levels of adiponectin and soluble vascular cell adhesion molecule-1 are associated with colorectal cancer risk. *World J Gastroenterol* 2012; **18**: 2805-2812 [PMID: 22719189 DOI: 10.3748/wjg.v18.i22.2805]

23 **Nakajima TE**, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, Hamaguchi T, Shimada Y. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. *Cancer Sci* 2010; **101**: 1286-1291 [PMID: 20331631 DOI: 10.1111/j.1349-7006.2010.01518.x]

24 **Lukanova A**, Söderberg S, Kaaks R, Jellum E, Stattin P. Serum adiponectin is not associated with risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 401-402 [PMID: 16492937 DOI: 10.1158/1055-9965.EPI-05-0836]

25 **Stattin P**, Palmqvist R, Söderberg S, Biessy C, Ardnor B, Hallmans G, Kaaks R, Olsson T. Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. *Oncol Rep* 2003; **10**: 2015-2021 [PMID: 14534736]

26 **Danese E**, Montagnana M, Minicozzi AM, Bonafini S, Ruzzenente O, Gelati M, De Manzoni G, Lippi G, Guidi GC. The role of resistin in colorectal cancer. *Clin Chim Acta* 2012; **413**: 760-764 [PMID: 22296675 DOI: 10.1016/j.cca.2012.01.019]

27 **Arpaci F**, Yilmaz MI, Ozet A, Ayta H, Ozturk B, Komurcu S, Ozata M. Low serum leptin level in colon cancer patients without significant weight loss. *Tumori* 2002; **88**: 147-149 [PMID: 12088256]

28 **Kumor A**, Daniel P, Pietruczuk M, Małecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. *Int J Colorectal Dis* 2009; **24**: 275-281 [PMID: 18979105 DOI: 10.1007/s00384-008-0605-y]

29 **Il'yasova D**, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, Kritchevsky SB. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. *Cancer Epidemiol Biomarkers Prev* 2005; **14**: 2413-2418 [PMID: 16214925 DOI: 10.1158/1055-9965.EPI-05-0316]

30 **Heikkilä K**, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, Ben-Shlomo Y, Ebrahim S, Lawlor DA. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. *Cancer Causes Control* 2009; **20**: 15-26 [PMID: 18704713 DOI: 10.1007/s10552-008-9212-z]

31 **Cochran WG**. The combination of estimates from different experiments. *Biom J* 1954; **10**: 101-129 [DOI: 0.2307/3001666]

32 **Higgins JP**, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; **21**: 1539-1558 [PMID: 12111919 DOI: 10.1002/sim.1186]

33 **Mantel N**, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 1959; **22**: 719-748 [PMID: 13655060]

34 **DerSimonian R**, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177-188 [PMID: 3802833]

35 **Begg CB**, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994; **50**: 1088-1101 [PMID: 7786990]

36 **Egger M**, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; **315**: 629-634 [PMID: 9310563]

37 **Paz-Filho G**, Lim EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. *Front Biosci* (Landmark Ed) 2011; **16**: 1634-1650 [PMID: 21196253]

38 **Gulcelik MA**, Colakoglu K, Dincer H, Dogan L, Yenidogan E, Gulcelik NE. Associations between adiponectin and two different cancers: breast and colon. *Asian Pac J Cancer Prev* 2012; **13**: 395-398 [PMID: 22502709]

39 **Kemik O**, Sumer A, Kemik AS, Hasirci I, Purisa S, Dulger AC, Demiriz B, Tuzun S. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. *World J Surg Oncol* 2010; **8**: 85 [PMID: 20920199 DOI: 10.1186/1477-7819-8-85]

40 **Wei EK**, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. *J Natl Cancer Inst* 2005; **97**: 1688-1694 [PMID: 16288122 DOI: 10.1093/jnci/dji376]

41 **Song M**, Zhang X, Wu K, Ogino S, Fuchs CS, Giovannucci EL, Chan AT. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. *Cancer Prev Res* (Phila) 2013; **6**: 875-885 [PMID: 23872505 DOI: 10.1158/1940-6207.CAPR-13-0169]

42 **Stocks T**, Lukanova A, Johansson M, Rinaldi S, Palmqvist R, Hallmans G, Kaaks R, Stattin P. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. *Int J Obes* (Lond) 2008; **32**: 304-314 [PMID: 17878894 DOI: 10.1038/sj.ijo.0803713]

43 **Chen MW**, Ye S, Zhao LL, Wang SY, Li YX, Yu CJ, Xie HJ, Wang YM. Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese male. *Med Oncol* 2012; **29**: 3129-3135 [PMID: 22752603 DOI: 10.1007/s12032-012-0280-2]

44 **Otake S**, Takeda H, Fujishima S, Fukui T, Orii T, Sato T, Sasaki Y, Nishise S, Kawata S. Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. *World J Gastroenterol* 2010; **16**: 1252-1257 [PMID: 20222170]

45 **An W**, Bai Y, Deng SX, Gao J, Ben QW, Cai QC, Zhang HG, Li ZS. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. *Eur J Cancer Prev* 2012; **21**: 126-133 [PMID: 21960184 DOI: 10.1097/CEJ.0b013e32834c9b55]

46 **Bolukbas FF**, Kilic H, Bolukbas C, Gumus M, Horoz M, Turhal NS, Kavakli B. Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study. *BMC Cancer* 2004; **4**: 29 [PMID: 15217519 DOI: 10.1186/1471-2407-4-29]

47 **Gialamas SP**, Sergentanis TN, Antonopoulos CN, Dessypris N, Chrousos GP, Petridou ET. Circulating leptin levels and risk of colorectal cancer and adenoma: a case-control study and meta-analysis. *Cancer Causes Control* 2013; **24**: 2129-2141 [PMID: 24085585 DOI: 10.1007/s10552-013-0290-1]

48 **Tamakoshi K**, Toyoshima H, Wakai K, Kojima M, Suzuki K, Watanabe Y, Hayakawa N, Yatsuya H, Kondo T, Tokudome S, Hashimoto S, Suzuki S, Kawado M, Ozasa K, Ito Y, Tamakoshi A. Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. *Oncology* 2005; **68**: 454-461 [PMID: 16020976 DOI: 10.1159/000086988]

49 **Stattin P**, Lukanova A, Biessy C, Söderberg S, Palmqvist R, Kaaks R, Olsson T, Jellum E. Obesity and colon cancer: does leptin provide a link? *Int J Cancer* 2004; **109**: 149-152 [PMID: 14735482 DOI: 10.1002/ijc.11668]

50 **Conroy SM**, Chai W, Lim U, Franke AA, Cooney RV, Maskarinec G. Leptin, adiponectin, and obesity among Caucasian and Asian women. *Mediators Inflamm* 2011; **2011**: 253580 [PMID: 21331287 DOI: 10.1155/2011/253580]

51 **Sălăgeanu A**, Tucureanu C, Lerescu L, Caraş I, Pitica R, Gangurà G, Costea R, Neagu S. Serum levels of adipokines resistin and leptin in patients with colon cancer. *J Med Life* 2010; **3**: 416-420 [PMID: 21254741]

52 **Gonullu G**, Kahraman H, Bedir A, Bektas A, Yücel I. Association between adiponectin, resistin, insulin resistance, and colorectal tumors. *Int J Colorectal Dis* 2010; **25**: 205-212 [PMID: 19888587 DOI: 10.1007/s00384-009-0828-6]

53 **Song M**, Wu K, Ogino S, Fuchs CS, Giovannucci EL, Chan AT. A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. *Br J Cancer* 2013; **108**: 1891-1898 [PMID: 23591192 DOI: 10.1038/bjc.2013.172]

54 **Chan AT**, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. *Gastroenterology* 2011; **140**: 799-808, quiz e11 [PMID: 21115010 DOI: 10.1053/j.gastro.2010.11.041]

**P-Reviewers:** Hoensch HP, Nayak BS **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Figure 1 Result of literature search for meta-analysis.**

**Figure 2 Meta-analysis for the association between adiponectin and colorectal cancer.**

**Figure 3 Meta-analysis for the association between leptin and colorectal cancer.**

|  |
| --- |
| **Table 1 Serum adipokine levels in patients with colorectal cancer and healthy controls *n* (%)** |
|   | Total (mean ± SD) | Case (mean ± sd) | Control (mean ± sd) | *P-*value |  |
| Age | 66.5±10.0 | 66.1±10.0 | 66.9±10.0 | 0.67 |  |
| ≤ 60 | 39 (19.5) | 20 (20.0) | 19 (19.0) |  |  |
| 61-70 | 87 (43.5) | 46 (46.0) | 41 (41.0) |  |  |
| 71 ≤ | 74 (37.0) | 34 (34.0) | 40 (40.0) |  |  |
| Sex |  |  |  | 1.00 |  |
| Male | 120 (60.0) | 60 (60.0) | 60 (60.0) |  |  |
| Female | 80 (40.0) | 40 (40.0) | 40 (40.0) |  |  |
| Serum levels |  |  |  |  |  |
| Adiponectin (μg/mL) | 6.0 ± 4.9 | 5.7 ± 4.4 | 6.2 ± 5.3 | 0.47 |  |
| Leptin (ng/mL) | 7.8 ± 8.9 | 6.8 ± 9.3 | 8.8 ± 8.5 | 0.12 |  |
| Resistin (ng/mL) | 3.9 ± 2.3 | 4.9 ± 2.3 | 2.8 ± 1.7 | < 0.0001 |  |
| IL-6 (pg/mL) | 21.0 ± 103.6 | 11.3 ± 11.8 | 30.8 ± 145.8 | 0.19 |  |
| TNFα (pg/mL) | 6.0 ± 13.2 | 6.4 ± 12.5 | 5.7 ± 13.9 | 0.68 |  |
| *P-*value for the comparison of cases and controls by *t* test or *χ2* test, as appropriate. |  |
|  |  |  |  |

|  |
| --- |
| **Table 2 Association between each obesity-related adipokine and colorectal cancer risk** |
|   | Case (*n* = 100) | Control (*n* = 100) | OR | OR1 |
|  | Adiponectin (μg/mL) |  |  |
| 1st tertile | 31 | 35 | ref. | ref. |
| 2nd tertile | 39 | 28 | 1.57 (0.79-3.12) | 1.76 (0.79-3.91) |
| 3rd tertile | 30 | 37 | 0.92 (0.46-1.81) | 0.80 (0.34-1.87) |
| *P-trend* |   |   | 0.80 | 0.65 |
|  | Leptin (ng/mL) |  |  |
| 1st tertile | 45 | 21 | ref. | ref. |
| 2nd tertile | 26 | 41 | 0.30 (0.15-0.60) | 0.37 (0.17-0.83) |
| 3rd tertile | 29 | 38 | 0.36 (0.18-0.72) | 0.31 (0.14-0.73) |
| *P-trend* |   |   | 0.05 | 0.01 |
|  | Resistin (ng/mL) |  |  |
| Low | 30 | 70 | ref. | ref. |
| High | 70 | 30 | 5.44 (2.97-9.97) | 6.08 (3.23-11.44) |
| *P-trend* |   |   | < 0.0001 | < 0.0001 |
|  | IL-6 (pg/mL) |  |  |
| 1st tertile | 43 | 25 | ref. | ref. |
| 2nd tertile | 26 | 42 | 0.36 (0.18-0.72) | 0.46 (0.21-1.01) |
| 3rd tertile | 31 | 33 | 0.55 (0.27-1.10) | 0.55 (0.24-1.26) |
| *P-trend* |   |   | 0.82 | 0.14 |
|  | TNFα (pg/mL) |  |  |
| 1st tertile | 14 | 54 | ref. | ref. |
| 2nd tertile | 34 | 32 | 4.10 (1.92-8.77) | 5.08 (1.84-13.10) |
| 3rd tertile | 52 | 14 | 14.33 (6.23-32.95) | 41.16 (12.62-134.23) |
| *P-trend* |   |   | < 0.01 | < 0.01 |
| OR: age, sex matched odds ratio; OR1: odds ratio after adjusting each obesity-related adipokines. |





